Consensus Amphastar Pharmaceuticals, Inc.

Stocks

AMPH

US03209R1032

Pharmaceuticals

Market Closed - Nasdaq 00:00:00 22/09/2026 +04			5-day change	1st Jan Change
24.48 ^USD	+3.64%		+2.38%	-8.59%

08-18	Barclays Adjusts Price Target on Amphastar Pharmaceuticals to $23 From $20, Maintains Equalweight Rating	MT
08-07	Amphastar Pharmaceuticals, Inc., Q2 2026 Earnings Call, Aug 06, 2026

Evolution of the Average Target: Amphastar Pharmaceuticals, Inc.

Evolution of the Target Price: Amphastar Pharmaceuticals, Inc.

Changes in Analyst Recommendations: Amphastar Pharmaceuticals, Inc.

ffa17e2e357270c6827a374b48ef831e.f-VYAGZs3j0MtEqmE3bafmWjloRQtCCe8DOYiOq1NJY.CZMiNl8nl18423vpSSW0DzXN-LAG_1PWxVnIpdzFW-wqlAozESCZRzvnPQ~f448590f23f00c061df8d6f56b97207a

Analysts' recommendations: Amphastar Pharmaceuticals, Inc.

08-18	Barclays Adjusts Price Target on Amphastar Pharmaceuticals to $23 From $20, Maintains Equalweight Rating	MT
06-29	BofA Securities Downgrades Amphastar Pharmaceuticals to Underperform From Neutral, Cuts Price Target to $20 From $25	MT
06-29	BofA Securities Downgrades Amphastar Pharmaceuticals to Underperform, $20 Price Target	MT
05-14	Amphastar Shares Fall After Wells Fargo Downgrade	MT
05-14	Wells Fargo Downgrades Amphastar Pharmaceuticals to Equalweight From Overweight, Adjusts PT to $19 From $30	MT
04-21	Jefferies Downgrades Amphastar Pharmaceuticals to Hold From Buy, Adjusts Price Target to $22 From $30	MT
01-07	BofA Securities Adjusts Price Target on Amphastar Pharmaceuticals to $30 From $31, Maintains Neutral Rating	MT
01-07	Biopharma Sector Enters 2026 With Clearer Outlook, Key Catalysts, BofA Says	MT
12-09	Barclays Initiates Amphastar Pharmaceuticals at Equalweight With $30 Price Target	MT
09/10/25	Ionis, Jazz Named Top Picks as US Biopharma Heads Into Steady Q3, BofA Says	MT
09/10/25	BofA Cuts Price Target on Amphastar Pharmaceuticals to $31 From $32	MT
12/08/25	Needham Upgrades Amphastar Pharmaceuticals to Buy From Hold, Price Target is $36	MT
12/05/25	JPMorgan Downgrades Amphastar Pharmaceuticals to Neutral From Overweight, Adjusts Price Target to $30 From $45	MT
21/04/25	BofA Adjusts Price Target on Amphastar Pharmaceuticals to $31 From $36	MT
04/02/25	Piper Sandler Downgrades Amphastar Pharmaceuticals to Neutral From Overweight, Adjusts Price Target to $36 From $66	MT
03/02/25	BofA Adjusts Price Target on Amphastar Pharmaceuticals to $44 From $46	MT
05/03/24	JPMorgan Initiates Amphastar Pharmaceuticals With Overweight Rating, Price Target is $60	MT
17/11/23	BofA Securities Initiates Amphastar Pharmaceuticals at Neutral Rating With $63 Price Target	MT
25/07/23	Jefferies Reinstates Buy Rating on Amphastar Pharmaceuticals With $70 Price Target	MT
17/05/23	Wells Fargo Adjusts Price Target on Amphastar Pharmaceuticals to $44 From $40, Maintains Equal-Weight Rating	MT
25/10/22	Piper Sandler Adjusts Amphastar Pharmaceuticals' Price Target to $40 From $43, Keeps Overweight Rating	MT
21/10/22	Jefferies Assumes Amphastar Pharmaceuticals at Buy with $36 Price Target	MT
29/07/22	Capital One Initiates Amphastar Pharmaceuticals at Overweight Rating With $44 Price Target	MT
11/04/22	Northland Adjusts Price Target on Amphastar Pharmaceuticals to $43 From $33, Keeps Outperform Rating	MT
08/04/22	Piper Sandler Raises Price Target for Amphastar Pharmaceuticals to $47 From $35, Maintains Overweight Rating	MT

More recommendations

Other Pharmaceuticals

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	AMPHASTAR PHARMACEUTICALS, INC.					-4.74%
	ELI LILLY AND COMPANY					+14.96%
	JOHNSON & JOHNSON					+2.93%
	ABBVIE INC.					+5.55%
	ROCHE HOLDING AG					+5.2%
	NOVARTIS AG					+9.33%
	ASTRAZENECA PLC					+26.44%
	AMGEN INC.					+0.53%
	NOVO NORDISK A/S					+10.16%
	GILEAD SCIENCES, INC.					+5.35%
	Average					+7.57%
	Weighted average by Cap.					+9.45%